Condition

Primary Mediastinal Large B Cell Lymphoma clinical trials and research

• 11Clinical trials
• 10Countries

Newest Primary Mediastinal Large B Cell Lymphoma clinical trials

All recruiting trials (11)

• Rituximab and Tafasitamab with Allogeneic NK Cells for relapsed or refractory B-cell NHL

  This trial tests whether giving allogeneic NK cells with Rituximab, Tafasitamab, and IL-2 can help people with relapsed or refractory B-cell non-Hodgkin lymphoma who have tried at least two prior therapies.

  Recruiting Phase 1 Case Comprehensive Cancer Center · Cleveland, Ohio and 1 other locations · NCT07225439

• Epcoritamab plus dose‑adjusted EPOCH‑R for aggressive B‑cell lymphoma

  This trial tests whether adding epcoritamab to dose‑adjusted EPOCH‑R chemotherapy can safely improve outcomes for adults with untreated aggressive B‑cell non‑Hodgkin lymphoma.

  Recruiting Phase 2 University of Washington · Seattle, Washington · NCT07097363

• Comparing advanced and classical immunotherapy for lymphoma treatment

  This study is testing whether newer immunotherapy treatments for high-grade B cell lymphoma work better and are safer than traditional methods for adults who have already had treatment that didn't work.

  Recruiting at 2 sites Seoul St. Mary's Hospital · Seoul and 1 other locations · NCT06796517

• Evaluating vaccine responses in patients with multiple myeloma and non-Hodgkin lymphoma after CAR-T treatment

  This study tests how well vaccines work in people with multiple myeloma and non-Hodgkin lymphoma after they have received CAR-T treatment.

  Recruiting OHSU Knight Cancer Institute · Portland, Oregon · NCT06784167

• Preventing CAR-T cell toxicities with emapalumab

  This study is testing if a drug called emapalumab can help prevent side effects in people with large B-cell non-Hodgkin's lymphoma who are receiving another treatment called axicabtagene ciloleucel.

  Recruiting Phase 2 Massachusetts General Hospital · Boston, Massachusetts and 1 other locations · NCT06550141

• Epcoritamab for B-cell lymphoma patients not fully responding to CAR-T therapy

  This study is testing if a new treatment called epcoritamab can help people with B-cell lymphoma who didn't fully respond to CAR-T therapy feel better and improve their chances of survival.

  Recruiting Phase 2 Academic and Community Cancer Research United · Rochester, Minnesota and 5 other locations · NCT06238648

• Combining pembrolizumab with CAR T-cell therapy for recurrent primary mediastinal large B-cell lymphoma

  This study is testing if adding pembrolizumab to CAR T-cell therapy can help people with recurrent primary mediastinal large B-cell lymphoma feel better and live longer.

  Recruiting at 2 sites Phase 2 Dana-Farber Cancer Institute · Boston, Massachusetts and 1 other locations · NCT05934448

• Evaluating SGR-1505 for treating mature B-cell neoplasms

  This study is testing a new oral medication called SGR-1505 to see if it is safe and effective for people with certain types of B-cell lymphomas that have not responded to other treatments.

  Recruiting at 36 sites Phase 1 Schrödinger, Inc. · Gilbert, Arizona and 35 other locations · NCT05544019

• Long-term follow-up of gene-edited immune cell therapy for lymphoma

  This study is checking how safe and effective a gene-edited immune cell therapy is for people with lymphoma who received the treatment in the past.

  Recruiting at 5 sites Pell Bio-Med Technology Co., Ltd. · Kaohsiung, Taiwan and 4 other locations · NCT05377307

• Using circulating tumor DNA to predict treatment response in lymphoma patients

  This study is testing if checking blood for tumor DNA can better predict how well lymphoma patients will respond to chemotherapy compared to traditional scans after their first two treatments.

  Recruiting Centre Henri Becquerel · Lyon and 1 other locations · NCT04824950

• Using modified T cells to treat relapsed or refractory Non-Hodgkin Lymphoma

  This study is testing a new treatment using modified T cells to see if it can help people with relapsed or hard-to-treat Non-Hodgkin Lymphoma.

  Recruiting Phase 1 University of California, San Francisco · San Francisco, California · NCT04545762

Related topics

Quick answers

How many Primary Mediastinal Large B Cell Lymphoma clinical trials are recruiting right now?

11, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 10 countries. The most sites are in United States (8 trials), France (2 trials), Taiwan (1 trial), Italy (1 trial), Moldova (1 trial). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 4, Phase 1: 3. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →